The 51st Annual Meeting of the European Society for Blood and Marrow Transplantation: Pharmacist Committee – Oral Session (O167-O168) - Top-Institutions - MDSpire

The 51st Annual Meeting of the European Society for Blood and Marrow Transplantation: Pharmacist Committee – Oral Session (O167-O168)

  • November 5, 2025

  • 0 min

Share

Top Institutions in Hematology

Brief introduction explaining scope and methodology.

  • #1

    Princess Máxima Center for Pediatric Oncology
    Princess Máxima Center for Pediatric Oncology

    Utrecht, Netherlands

    Key Differentiators

    • Pediatric Oncology
    • Hematology
    • Infectious Diseases
    • Pharmacology

  • #2

    Radboud University Medical Center
    Radboud University Medical Center

    Nijmegen, Netherlands

    Key Differentiators

    • Mycology
    • Infectious Diseases
    • Hematology

  • #3

    St. Jude Children’s Research Hospital
    St. Jude Children’s Research Hospital

    Memphis, Tennessee

    Key Differentiators

    • Pediatric Oncology
    • Infectious Diseases
    • Pharmacology

  • #4

    Dana-Farber/Boston Children’s Cancer and Blood Disorders Center
    Dana-Farber/Boston Children’s Cancer and Blood Disorders Center

    Boston, Massachusetts

    Key Differentiators

    • Pediatric Hematology-Oncology
    • Infectious Diseases

  • #5

    Fred Hutchinson Cancer Center
    Fred Hutchinson Cancer Center

    Seattle, Washington

    Key Differentiators

    • Hematology
    • Stem Cell Transplantation
    • Infectious Diseases

Original Source(s)

The 51st Annual Meeting of the European Society for Blood and Marrow Transplantation: Pharmacist Committee – Oral Session (O167-O168)

  • November 5, 2025

Related Content

Partly intraoperative cell salvage in pediatric craniocerebral trauma: effects on coagulation function, allogeneic blood requirements, and clinical outcomes — a propensity score-matched retrospective cohort study

Case Report: Massive rectal bleeding from stercoral ulcers in a pediatric patient

Treatment Intensity in the Frontline Setting for Transplant-Ineligible Patients With Multiple Myeloma

The management of newly diagnosed transplant-ineligible multiple myeloma remains challenging, in part due to the complexity of treatment decisions for frail patients. Recent subgroup analyses provide insight into whether quadruplet therapy may offer advantages over triplet therapy in this population.